Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial
The efficacy and acceptability of 5 mg nebivolol once daily, a long-acting, vasodilating cardioselective beta blocker that additionally facilitates the L-arginine/nitric oxide system, was assessed in a double-blind, randomized trial in comparison with 20 mg nifedipine retard twice daily in patients...
Gespeichert in:
| Veröffentlicht in: | American journal of therapeutics 1998-07, Vol.5 (4), p.237-244 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 4 |
| container_start_page | 237 |
| container_title | American journal of therapeutics |
| container_volume | 5 |
| creator | Van Nueten, L Lacourcière, Y Vyssoulis, G Korlipara, K Marcadet, D M Dupont, A G Robertson, J I |
| description | The efficacy and acceptability of 5 mg nebivolol once daily, a long-acting, vasodilating cardioselective beta blocker that additionally facilitates the L-arginine/nitric oxide system, was assessed in a double-blind, randomized trial in comparison with 20 mg nifedipine retard twice daily in patients with essential hypertension. At 2 weeks of treatment, nebivolol was significantly more effective. Thereafter, both drugs effectively and similarly lowered systolic and diastolic pressures without orthostatic effect. Nebivolol had a trough-to-peak antihypertensive effect ratio of 90%. Nifedipine gave the expected side effects of headache, flushing, and edema. Nebivolol was well tolerated. Nebivolol slightly but significantly lowered heart rate. Neither drug adversely affected plasma levels of lipids. |
| doi_str_mv | 10.1097/00045391-199807000-00006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79612306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79612306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c171t-b6ebe270c14e867375647ceef34e9592fb9edcb6e89cdbc66c6ac6f3e9f35f1e3</originalsourceid><addsrcrecordid>eNpNkEtPwzAQhH0A0VL4C8gnTgTsPOyYG6p4SRVc4Gw5zlo1SuxgJ5XKr8elBXFY7aw0Myt9CGFKrikR_IYQUlaFoBkVoiY8nVkawo7QnBJeZTln1QydxvhBCM1rWp6gGSVECMKqOZpeoLEb3_kObyDEKWJnDbR2sA6wdXhcAx4DqLEHN2JvMMSYlFUdXm8HCCO4aL27xQq3fmo6yJrOuvYKB-Va39svSFr7flBBjXazK0vZM3RsVBfh_LAX6P3h_m35lK1eH5-Xd6tMU07HrGHQQM6JpiXUjBe8YiXXAKYoQVQiN42AVidXLXTbaMY0U5qZAoQpKkOhWKDLfe8Q_OcEcZS9jRq6TjnwU5RcMJoXhCVjvTfq4GMMYOQQbK_CVlIid5jlL2b5h1n-YE7Ri8OPqemh_RfcMy6-ActkfdA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79612306</pqid></control><display><type>article</type><title>Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Van Nueten, L ; Lacourcière, Y ; Vyssoulis, G ; Korlipara, K ; Marcadet, D M ; Dupont, A G ; Robertson, J I</creator><creatorcontrib>Van Nueten, L ; Lacourcière, Y ; Vyssoulis, G ; Korlipara, K ; Marcadet, D M ; Dupont, A G ; Robertson, J I</creatorcontrib><description>The efficacy and acceptability of 5 mg nebivolol once daily, a long-acting, vasodilating cardioselective beta blocker that additionally facilitates the L-arginine/nitric oxide system, was assessed in a double-blind, randomized trial in comparison with 20 mg nifedipine retard twice daily in patients with essential hypertension. At 2 weeks of treatment, nebivolol was significantly more effective. Thereafter, both drugs effectively and similarly lowered systolic and diastolic pressures without orthostatic effect. Nebivolol had a trough-to-peak antihypertensive effect ratio of 90%. Nifedipine gave the expected side effects of headache, flushing, and edema. Nebivolol was well tolerated. Nebivolol slightly but significantly lowered heart rate. Neither drug adversely affected plasma levels of lipids.</description><identifier>ISSN: 1075-2765</identifier><identifier>DOI: 10.1097/00045391-199807000-00006</identifier><identifier>PMID: 10099065</identifier><language>eng</language><publisher>United States</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Adult ; Aged ; Antihypertensive Agents - therapeutic use ; Benzopyrans - therapeutic use ; Blood Pressure - drug effects ; Calcium Channel Blockers - therapeutic use ; Double-Blind Method ; Ethanolamines - therapeutic use ; Female ; Heart Rate - drug effects ; Humans ; Hypertension - drug therapy ; Male ; Middle Aged ; Nebivolol ; Nifedipine - therapeutic use ; Treatment Outcome</subject><ispartof>American journal of therapeutics, 1998-07, Vol.5 (4), p.237-244</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10099065$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Nueten, L</creatorcontrib><creatorcontrib>Lacourcière, Y</creatorcontrib><creatorcontrib>Vyssoulis, G</creatorcontrib><creatorcontrib>Korlipara, K</creatorcontrib><creatorcontrib>Marcadet, D M</creatorcontrib><creatorcontrib>Dupont, A G</creatorcontrib><creatorcontrib>Robertson, J I</creatorcontrib><title>Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial</title><title>American journal of therapeutics</title><addtitle>Am J Ther</addtitle><description>The efficacy and acceptability of 5 mg nebivolol once daily, a long-acting, vasodilating cardioselective beta blocker that additionally facilitates the L-arginine/nitric oxide system, was assessed in a double-blind, randomized trial in comparison with 20 mg nifedipine retard twice daily in patients with essential hypertension. At 2 weeks of treatment, nebivolol was significantly more effective. Thereafter, both drugs effectively and similarly lowered systolic and diastolic pressures without orthostatic effect. Nebivolol had a trough-to-peak antihypertensive effect ratio of 90%. Nifedipine gave the expected side effects of headache, flushing, and edema. Nebivolol was well tolerated. Nebivolol slightly but significantly lowered heart rate. Neither drug adversely affected plasma levels of lipids.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Benzopyrans - therapeutic use</subject><subject>Blood Pressure - drug effects</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Ethanolamines - therapeutic use</subject><subject>Female</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nebivolol</subject><subject>Nifedipine - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1075-2765</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkEtPwzAQhH0A0VL4C8gnTgTsPOyYG6p4SRVc4Gw5zlo1SuxgJ5XKr8elBXFY7aw0Myt9CGFKrikR_IYQUlaFoBkVoiY8nVkawo7QnBJeZTln1QydxvhBCM1rWp6gGSVECMKqOZpeoLEb3_kObyDEKWJnDbR2sA6wdXhcAx4DqLEHN2JvMMSYlFUdXm8HCCO4aL27xQq3fmo6yJrOuvYKB-Va39svSFr7flBBjXazK0vZM3RsVBfh_LAX6P3h_m35lK1eH5-Xd6tMU07HrGHQQM6JpiXUjBe8YiXXAKYoQVQiN42AVidXLXTbaMY0U5qZAoQpKkOhWKDLfe8Q_OcEcZS9jRq6TjnwU5RcMJoXhCVjvTfq4GMMYOQQbK_CVlIid5jlL2b5h1n-YE7Ri8OPqemh_RfcMy6-ActkfdA</recordid><startdate>199807</startdate><enddate>199807</enddate><creator>Van Nueten, L</creator><creator>Lacourcière, Y</creator><creator>Vyssoulis, G</creator><creator>Korlipara, K</creator><creator>Marcadet, D M</creator><creator>Dupont, A G</creator><creator>Robertson, J I</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199807</creationdate><title>Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial</title><author>Van Nueten, L ; Lacourcière, Y ; Vyssoulis, G ; Korlipara, K ; Marcadet, D M ; Dupont, A G ; Robertson, J I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c171t-b6ebe270c14e867375647ceef34e9592fb9edcb6e89cdbc66c6ac6f3e9f35f1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Benzopyrans - therapeutic use</topic><topic>Blood Pressure - drug effects</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Ethanolamines - therapeutic use</topic><topic>Female</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nebivolol</topic><topic>Nifedipine - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Nueten, L</creatorcontrib><creatorcontrib>Lacourcière, Y</creatorcontrib><creatorcontrib>Vyssoulis, G</creatorcontrib><creatorcontrib>Korlipara, K</creatorcontrib><creatorcontrib>Marcadet, D M</creatorcontrib><creatorcontrib>Dupont, A G</creatorcontrib><creatorcontrib>Robertson, J I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Nueten, L</au><au>Lacourcière, Y</au><au>Vyssoulis, G</au><au>Korlipara, K</au><au>Marcadet, D M</au><au>Dupont, A G</au><au>Robertson, J I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial</atitle><jtitle>American journal of therapeutics</jtitle><addtitle>Am J Ther</addtitle><date>1998-07</date><risdate>1998</risdate><volume>5</volume><issue>4</issue><spage>237</spage><epage>244</epage><pages>237-244</pages><issn>1075-2765</issn><abstract>The efficacy and acceptability of 5 mg nebivolol once daily, a long-acting, vasodilating cardioselective beta blocker that additionally facilitates the L-arginine/nitric oxide system, was assessed in a double-blind, randomized trial in comparison with 20 mg nifedipine retard twice daily in patients with essential hypertension. At 2 weeks of treatment, nebivolol was significantly more effective. Thereafter, both drugs effectively and similarly lowered systolic and diastolic pressures without orthostatic effect. Nebivolol had a trough-to-peak antihypertensive effect ratio of 90%. Nifedipine gave the expected side effects of headache, flushing, and edema. Nebivolol was well tolerated. Nebivolol slightly but significantly lowered heart rate. Neither drug adversely affected plasma levels of lipids.</abstract><cop>United States</cop><pmid>10099065</pmid><doi>10.1097/00045391-199807000-00006</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1075-2765 |
| ispartof | American journal of therapeutics, 1998-07, Vol.5 (4), p.237-244 |
| issn | 1075-2765 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79612306 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adrenergic beta-Antagonists - therapeutic use Adult Aged Antihypertensive Agents - therapeutic use Benzopyrans - therapeutic use Blood Pressure - drug effects Calcium Channel Blockers - therapeutic use Double-Blind Method Ethanolamines - therapeutic use Female Heart Rate - drug effects Humans Hypertension - drug therapy Male Middle Aged Nebivolol Nifedipine - therapeutic use Treatment Outcome |
| title | Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A20%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nebivolol%20versus%20nifedipine%20in%20the%20treatment%20of%20essential%20hypertension:%20a%20double-blind,%20randomized,%20comparative%20trial&rft.jtitle=American%20journal%20of%20therapeutics&rft.au=Van%20Nueten,%20L&rft.date=1998-07&rft.volume=5&rft.issue=4&rft.spage=237&rft.epage=244&rft.pages=237-244&rft.issn=1075-2765&rft_id=info:doi/10.1097/00045391-199807000-00006&rft_dat=%3Cproquest_cross%3E79612306%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79612306&rft_id=info:pmid/10099065&rfr_iscdi=true |